Samsung Medical Center
En Corée du Sud, les thérapies ciblées coûtent généralement entre $5,500 et $11,500. Le coût final dépend du médicament prescrit, du profil mutationnel et du type d'établissement hospitalier. En France, les patients déboursent en moyenne $16,500 pour des soins oncologiques similaires. Choisir la Corée du Sud permet d'économiser environ 48 %. Ces tarifs incluent habituellement les médicaments, les consultations spécialisées et le suivi diagnostique indispensable.
Avis d'expert Bookimed : L'hôpital universitaire de Séoul Bundang (SNUBH) apporte une valeur unique en tant que premier hôpital entièrement numérique sud-coréen. Cette technologie réduit les risques d'erreurs médicales. Pour des soins d'excellence, le Samsung Medical Center et l'hôpital de l'université nationale de Séoul (SNUH) sont des références. Newsweek les classe régulièrement parmi les meilleurs hôpitaux au monde. Des structures comme le Severance Hospital ou l'hôpital universitaire Korea Anam possèdent l'accréditation JCI. Elles garantissent des normes de sécurité occidentales tout en offrant des économies substantielles.
Pourquoi les patients choisissent-ils la République de Corée pour la thérapie ciblée ?
Accédez à des solutions avancées de thérapie ciblée dans des cliniques de confiance .
| République de Corée | Turquie | Espagne | |
| Thérapie ciblée | de $5,500 | de $1,000 | de $15,000 |
| Thérapie au lutétium-177 | de $13,500 | de $8,800 | de $12,000 |
| Thérapie à l'actinium-225 | - | de $22,955 | de $45,000 |
| Oncothermie | - | de $450 | - |
Bookimed ne facture pas de frais supplémentaires pour les prix des Thérapie ciblée. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Thérapie ciblée.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Thérapie ciblée et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Thérapie ciblée.
Jour 1 : Arrivée
Jour 2 : étape pré-opérationnelle
Jour 3 : Thérapie ciblée
Jour 4 : étape postopératoire
Semaine 1-2 : Rééducation
Veuillez noter que le cas de chaque patient est individuel et peut varier.
South Korea offers extensive targeted therapy for common cancers like lung, breast, and colorectal but does not cover every type. Availability depends on specific genetic mutations identified through NGS testing. Major institutions like Samsung Medical Center and Severance Hospital provide advanced drugs for cases with approved biomarkers.
Bookimed Expert Insight: While targeted therapy costs start at $5,500, real-world value comes from South Korea’s rapid drug approval cycle. Samsung Medical Center and Seoul National University Hospital often provide access to new therapies years before other regions. This makes Korea a strategic choice for patients seeking the latest FDA-approved molecules that are not yet regional standards.
Patient Consensus: Patients emphasize getting NGS biomarker testing early at major hospitals to unlock treatment options. Many travelers note that while drugs for common mutations are accessible, off-label treatments for rare cases remain expensive without local insurance.
South Korea's top hospitals for targeted therapy include Samsung Medical Center, Severance Hospital, and Seoul National University Hospital. These institutions distinguish themselves through high-volume genomic analysis, Next-Generation Sequencing, and multidisciplinary teams that match specific genetic mutations to precise drug regimens for complex cancers.
Bookimed Expert Insight: Samsung Medical Center and Seoul National University Hospital serve a combined 3.6 million patients annually. This massive volume allows their specialists to encounter rare genetic mutations more frequently than most Western centers. This deep data pool directly improves the accuracy of their Next-Generation Sequencing panels for therapy matching.
Patient Consensus: Patients value the speed of genomic mapping, which often takes only days. Many suggest requesting Next-Generation Sequencing upfront to ensure the most effective therapy match immediately.
South Korean National Health Insurance (NHI) covers many targeted therapies, typically reducing patient costs to 5% of the total medical bill for reimbursed treatments. Coverage depends on specific drug approval for the patient's cancer type and stage as determined by the Health Insurance Review and Assessment Service (HIRA).
Bookimed Expert Insight: While NHI offers significant savings, university hospitals like Severance Hospital or Samsung Medical Center often have higher approval odds for complex cases. These top-tier facilities participate in international clinical trials, providing access to cutting-edge therapies before they reach the official reimbursement list.
Patient Consensus: Patients report that while coverage is generous compared to US costs, the bureaucracy can cause delays. Many recommend bringing detailed genetic reports to speed up the authorization process at major Seoul hospitals.
South Korea accelerates access to targeted drugs through the GIFT (Global Innovative Products on Fast Track) system and the 2025 approval reforms. These pathways prioritize severe or rare diseases. They aim to reduce regulatory review timelines from 420 days to approximately 295 days.
Bookimed Expert Insight: Samsung Medical Center and Severance Hospital often provide the fastest access through named patient programs. These programs allow patients to receive new drugs 3–6 months before official reimbursement. In some cases, these medications are available at 20–50% of the standard US price.
Patient Consensus: Patients report that the prior approval system through major Seoul hospitals can secure insurance coverage for advanced lung cancer drugs like Tagrisso within just a few days.
The Ministry of Food and Drug Safety (MFDS) supervises targeted therapy in the Republic of Korea under the Pharmaceutical Affairs Act. This framework distinguishes between small-molecule drugs and advanced biological products. Specialized systems like the GIFT program and ARMAB Act accelerate access to innovative cancer treatments.
Bookimed Expert Insight: Clinical data from top-tier institutions like Samsung Medical Center and Seoul National University Hospital shows a unique regulatory advantage. These major academic centers often navigate the MFDS approval process for targeted therapies 6 to 12 months faster than the FDA. This speed allows patients to access newer Japanese or European therapies before they reach the US market.
Patient Consensus: Patients emphasize that MFDS approval does not guarantee insurance coverage. Many coordinate with hospital networks to manage out-of-pocket costs for non-reimbursed agents through pharmaceutical assistance programs.